RxDoctor Payments Data

Stephanie Merica, NP

Acute Care · Rochester, NYNPI 1588271944

Payments from drug & device makers

$1,186in general payments, 2019–2025

Across 59 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$375
  • Edwards Lifesciences$135
  • Boehringer Ingelheim$107
  • Kiniksa Pharmaceuticals International, PLC$86
  • Merck$78
  • Amgen$75
  • plus $330 from 8 others

What the payments were for

  • Food & beverage$1,186100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,186 in reported general payments places this provider in the 80th percentile of 980 acute care providers in New York.

See all acute care providers in New York

Medicare billing

Part B allowed, 2024
$10,970
Medicare patients
104
Services billed
228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban233$301,162
EntrestoSacubitril/Valsartan82$95,502
JardianceEmpagliflozin65$88,319
FarxigaDapagliflozin Propanediol68$72,100
Repatha SureclickEvolocumab57$69,979
XareltoRivaroxaban42$57,167
Metoprolol Succinate482$9,270
Rosuvastatin Calcium325$6,498
Atorvastatin Calcium321$5,064
Ezetimibe123$4,764
Ranolazine ErRanolazine32$3,891
Dofetilide16$3,449
Nadolol33$2,755
Losartan Potassium151$2,337
Digoxin55$1,969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$74$301,162233 claims
NovartisEntresto$375$95,50282 claims
Boehringer IngelheimJardiance$107$88,31965 claims
Johnson & JohnsonXarelto$14$57,16742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 980 acute care providers in New York.

Other acute care in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →